Published in Pediatr Blood Cancer on October 01, 2010
Detection of KIAA1549-BRAF fusion transcripts in formalin-fixed paraffin-embedded pediatric low-grade gliomas. J Mol Diagn (2011) 1.11
Childhood brain tumors: epidemiology, current management and future directions. Nat Rev Neurol (2011) 1.09
Current Understanding of BRAF Alterations in Diagnosis, Prognosis, and Therapeutic Targeting in Pediatric Low-Grade Gliomas. Front Oncol (2015) 1.02
A review of targeted therapies evaluated by the pediatric preclinical testing program for osteosarcoma. Front Oncol (2013) 0.95
Ras/Raf/MEK/ERK Pathway Activation in Childhood Acute Lymphoblastic Leukemia and Its Therapeutic Targeting. Front Oncol (2014) 0.93
Development, characterization, and reversal of acquired resistance to the MEK1 inhibitor selumetinib (AZD6244) in an in vivo model of childhood astrocytoma. Clin Cancer Res (2013) 0.92
Advances in therapeutic development for spinal muscular atrophy. Future Med Chem (2014) 0.89
Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am (2014) 0.87
Molecular profiling of childhood cancer: Biomarkers and novel therapies. BBA Clin (2014) 0.86
New strategies in pediatric gliomas: molecular advances in pediatric low-grade gliomas as a model. Clin Cancer Res (2013) 0.84
Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro Oncol (2016) 0.83
Biologically targeted therapeutics in pediatric brain tumors. Pediatr Neurol (2012) 0.80
Exploiting molecular biology for diagnosis and targeted management of pediatric low-grade gliomas. Future Oncol (2016) 0.79
Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression. Mol Cancer Ther (2015) 0.79
The molecular biology of WHO grade I astrocytomas. Neuro Oncol (2012) 0.79
Initial testing (stage 1) of ganetespib, an Hsp90 inhibitor, by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer (2013) 0.78
Pharmacodynamic and genomic markers associated with response to the XPO1/CRM1 inhibitor selinexor (KPT-330): A report from the pediatric preclinical testing program. Pediatr Blood Cancer (2015) 0.77
A review of new agents evaluated against pediatric acute lymphoblastic leukemia by the Pediatric Preclinical Testing Program. Leukemia (2016) 0.76
Review of low-grade gliomas in children--evolving molecular era and therapeutic insights. Childs Nerv Syst (2015) 0.76
Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma. Pediatr Blood Cancer (2015) 0.75
Challenges in Drug Discovery for Neurofibromatosis Type 1-Associated Low-Grade Glioma. Front Oncol (2016) 0.75
Relevance of Fusion Genes in Pediatric Cancers: Toward Precision Medicine. Mol Ther Nucleic Acids (2017) 0.75
Preclinical Childhood Sarcoma Models: Drug Efficacy Biomarker Identification and Validation. Front Oncol (2015) 0.75
Targeted Therapy for MAPK Alterations in Pediatric Gliomas. Brain Disord Ther (2015) 0.75
The use of novel selectivity metrics in kinase research. BMC Bioinformatics (2017) 0.75
Actionable molecular biomarkers in primary brain tumors. Trends Cancer (2016) 0.75
Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Res (2016) 0.75
Mutations of the BRAF gene in human cancer. Nature (2002) 65.42
Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell (2004) 19.51
BRAF mutation predicts sensitivity to MEK inhibition. Nature (2005) 17.14
MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A (2009) 6.58
Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res (2008) 6.44
Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res (2007) 5.59
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Guilty as charged: B-RAF is a human oncogene. Cancer Cell (2004) 4.97
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol (2008) 4.82
BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. J Clin Invest (2008) 3.98
Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas. J Pathol (2009) 3.32
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res (2009) 3.21
Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood (2004) 3.13
The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res (2008) 2.64
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35
Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma. Oncogene (2009) 2.26
The first-in-human study of the hydrogen sulfate (Hyd-sulfate) capsule of the MEK1/2 inhibitor AZD6244 (ARRY-142886): a phase I open-label multicenter trial in patients with advanced cancer. Clin Cancer Res (2010) 2.17
Mutations in the BRAF and N-ras genes in childhood acute lymphoblastic leukaemia. Leukemia (2005) 1.95
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95
Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. Cancer Res (1988) 1.86
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models. Clin Cancer Res (2005) 1.83
Mutation of genes affecting the RAS pathway is common in childhood acute lymphoblastic leukemia. Cancer Res (2008) 1.77
Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin Cancer Res (2006) 1.58
Targeting protein translation in human non small cell lung cancer via combined MEK and mammalian target of rapamycin suppression. Cancer Res (2007) 1.55
Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas. Acta Neuropathol (2004) 1.55
Differential regulation of vascular endothelial growth factor by Akt and mammalian target of rapamycin inhibitors in cell lines derived from childhood solid tumors. Mol Cancer Ther (2007) 1.28
Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia. Hematol J (2002) 1.16
Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol (2009) 1.01
Hotspot mutations of BRAF gene are not associated with pediatric solid neoplasms. Oncol Rep (2004) 0.93
Mutations in PIK3CA are infrequent in neuroblastoma. BMC Cancer (2006) 0.93
Mutational analysis of PDGFR-RAS/MAPK pathway activation in childhood medulloblastoma. Eur J Cancer (2006) 0.91
Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med (2011) 11.01
The TOR pathway: a target for cancer therapy. Nat Rev Cancer (2004) 9.02
The genetic landscape of the childhood cancer medulloblastoma. Science (2010) 8.34
Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol (2002) 8.03
Identification of ALK as a major familial neuroblastoma predisposition gene. Nature (2008) 7.38
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med (2010) 6.34
HIF1alpha-dependent glycolytic pathway orchestrates a metabolic checkpoint for the differentiation of TH17 and Treg cells. J Exp Med (2011) 5.99
Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. N Engl J Med (2014) 5.37
The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer (2007) 5.28
Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study. J Clin Oncol (2009) 5.12
Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med (2005) 4.92
Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res (2002) 4.90
The genetic landscape of high-risk neuroblastoma. Nat Genet (2013) 4.71
Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res (2009) 4.53
The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med (2004) 4.28
Adjustment of genomic waves in signal intensities from whole-genome SNP genotyping platforms. Nucleic Acids Res (2008) 4.22
Copy number variation at 1q21.1 associated with neuroblastoma. Nature (2009) 4.10
Germline genomic variants associated with childhood acute lymphoblastic leukemia. Nat Genet (2009) 3.71
Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature (2010) 3.70
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol (2013) 3.70
The genomic landscape of hypodiploid acute lymphoblastic leukemia. Nat Genet (2013) 3.43
Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood (2011) 3.40
Integrated genomic analyses identify ARID1A and ARID1B alterations in the childhood cancer neuroblastoma. Nat Genet (2012) 3.38
Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol (2005) 3.36
Biology and therapeutic advances for pediatric osteosarcoma. Oncologist (2004) 3.34
STAC: A method for testing the significance of DNA copy number aberrations across multiple array-CGH experiments. Genome Res (2006) 3.21
Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res (2004) 3.20
The tumor suppressor Tsc1 enforces quiescence of naive T cells to promote immune homeostasis and function. Nat Immunol (2011) 3.03
Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP). Pediatr Blood Cancer (2010) 2.99
Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med (2014) 2.92
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
A functional screen identifies miR-34a as a candidate neuroblastoma tumor suppressor gene. Mol Cancer Res (2008) 2.77
Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA (2009) 2.72
The majority of total nuclear-encoded non-ribosomal RNA in a human cell is 'dark matter' un-annotated RNA. BMC Biol (2010) 2.59
Establishment of human tumor xenografts in immunodeficient mice. Nat Protoc (2007) 2.54
Common variations in BARD1 influence susceptibility to high-risk neuroblastoma. Nat Genet (2009) 2.47
Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. Cancer Res (2006) 2.42
mTORC1 couples immune signals and metabolic programming to establish T(reg)-cell function. Nature (2013) 2.38
Pharmacokinetic, pharmacodynamic, and pharmacogenetic determinants of osteonecrosis in children with acute lymphoblastic leukemia. Blood (2010) 2.37
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther (2007) 2.35
Rapamycins: mechanism of action and cellular resistance. Cancer Biol Ther (2003) 2.31
Messenger RNA expression levels of CXCR4 correlate with metastatic behavior and outcome in patients with osteosarcoma. Clin Cancer Res (2005) 2.31
mTORC1 signaling under hypoxic conditions is controlled by ATM-dependent phosphorylation of HIF-1α. Mol Cell (2010) 2.27
Acetylcholinesterase inhibitors from plants. Phytomedicine (2007) 2.25
The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood (2005) 2.25
Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol (2013) 2.25
Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol (2003) 2.24
Leads from Indian medicinal plants with hypoglycemic potentials. J Ethnopharmacol (2006) 2.21
Genome-wide association study identifies two susceptibility loci for osteosarcoma. Nat Genet (2013) 2.21
Integrative genomics identifies LMO1 as a neuroblastoma oncogene. Nature (2010) 2.21
Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer (2004) 2.20
Chemotherapy resistance in osteosarcoma: current challenges and future directions. Expert Rev Anticancer Ther (2006) 2.19
Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature (2006) 2.12
Host genetic variation affects resistance to infection with a highly pathogenic H5N1 influenza A virus in mice. J Virol (2009) 2.08
Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: from binding promiscuity to selective inhibition. Chem Biol (2003) 2.05
Genomic copy number determination in cancer cells from single nucleotide polymorphism microarrays based on quantitative genotyping corrected for aneuploidy. Genome Res (2009) 2.02
E2-RING expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell (2009) 1.98
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med (2011) 1.96
Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation. Cancer Cell (2005) 1.95
Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program. Pediatr Blood Cancer (2008) 1.95
Therapy for osteosarcoma: where do we go from here? Paediatr Drugs (2008) 1.95
The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev (2008) 1.93
Dickkopf 3 inhibits invasion and motility of Saos-2 osteosarcoma cells by modulating the Wnt-beta-catenin pathway. Cancer Res (2004) 1.93
Deep neuromuscular blockade during spinal surgery reduces intra-operative blood loss: A randomised clinical trial. Eur J Anaesthesiol (2020) 1.92
Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol (2010) 1.92
A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group. Clin Cancer Res (2006) 1.91
Lost in translation: dysregulation of cap-dependent translation and cancer. Cancer Cell (2004) 1.91
RNAi screen of the protein kinome identifies checkpoint kinase 1 (CHK1) as a therapeutic target in neuroblastoma. Proc Natl Acad Sci U S A (2011) 1.90
IGF-I mediated survival pathways in normal and malignant cells. Biochim Biophys Acta (2006) 1.88
Definition and characterization of a region of 1p36.3 consistently deleted in neuroblastoma. Oncogene (2005) 1.86
Improved response in high-risk neuroblastoma with protracted topotecan administration using a pharmacokinetically guided dosing approach. J Clin Oncol (2005) 1.85
Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell (2003) 1.84
Molecular characterization of the pediatric preclinical testing panel. Clin Cancer Res (2008) 1.84